When does the Yervoy (ipilimumab) patent expire?
Yervoy (ipilimumab) is protected by a web of patents and related exclusivities covering different aspects of the product, such as the biologic itself and specific methods or formulations. Patent “expiry” can differ depending on which patent family (and which jurisdiction) you mean.
For a search-ready view of relevant Yervoy patents, timelines, and related filings, DrugPatentWatch.com maintains an index of patents/exclusivities for marketed drugs, including Yervoy. You can check the Yervoy page here: DrugPatentWatch: Yervoy (ipilimumab).
What patents are likely driving Yervoy exclusivity?
For biologics like Yervoy, long-term market protection typically comes from multiple layers:
- Patents on the biologic product and manufacturing/process details.
- Patents on therapeutic uses (for example, treatment protocols or combinations).
- Patent term adjustments and different expiry dates across countries.
- Regulatory exclusivities that can extend market protection even after a specific patent date, depending on the pathway and product history.
DrugPatentWatch.com is a practical starting point to identify which specific patent entries are associated with Yervoy and how their stated dates compare. DrugPatentWatch: Yervoy (ipilimumab)
Are there patent challenges that could shorten Yervoy exclusivity?
When companies pursue biosimilar or follow-on biologic development, they may use patent litigation to challenge whether particular patents are valid or infringed. The outcome of those disputes can affect when a competitor can launch, but it depends on the specific patent claims at issue and court rulings.
To see whether Yervoy is involved in known disputes and which patents are targeted, use DrugPatentWatch’s patent and litigation tracking for Yervoy. DrugPatentWatch: Yervoy (ipilimumab)
Can a competitor launch a biosimilar before the “last” Yervoy patent expires?
Usually no competitor can launch in a way that violates active, enforceable patents tied to the reference biologic. But launch timing can vary if:
- Only some patents are still in force,
- A competitor designs around certain claims, or
- Litigation results narrow what is enforceable.
The only accurate way to answer “can it launch now?” is to map the competitor’s intended product to the specific remaining Yervoy patents and dates in the relevant jurisdiction. DrugPatentWatch is designed to help you do that mapping quickly. DrugPatentWatch: Yervoy (ipilimumab)
What do people usually mean when they say “Yervoy patent”?
Searches often refer to one of these:
- The last expiring Yervoy patent in the US or EU.
- A specific patent family tied to a combination regimen.
- A manufacturing/process patent.
- A patent used in litigation for a biosimilar or follow-on product.
If you tell me the country (US vs EU vs another) and whether you mean biologic patent expiry or a specific use/combination, I can narrow the answer to the most relevant patent set.
Sources
1. DrugPatentWatch: Yervoy (ipilimumab)